Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study

Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study

https://www.boehringer-ingelheim.com/press-release/type-2-diabetes-investigation...

Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

More News: Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Jardiance | Research | Study